<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346567</url>
  </required_header>
  <id_info>
    <org_study_id>comtru</org_study_id>
    <nct_id>NCT00346567</nct_id>
  </id_info>
  <brief_title>Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)</brief_title>
  <official_title>Clinical Trial: Backup With Combivir (AZT/3TC) or Single Dose (sd) Truvada (FTC/TDF) in Order to Avoid NNRTI Resistance After sd Nevirapine for the Prevention of Mother-to-child Transmission (MTCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <brief_summary>
    <textblock>
      The aim of the study is to find short course alternatives to single dose (sd)nevirapine for
      the prevention of mother-to-child HIV-transmission with the same or better degree of
      transmission protection than sd nevirapine but with less NNRTI resistance development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomised open study comparing Zidovudine from 28 weeks gestation, single dose Nevirapine +
      1 week of Combivir with Zidovudine from 28 weeks gestation, single dose Nevirapine + single
      dose of Truvada for the mothers during birth. In both arms the infants will receive one dose
      of nevirapine within the first days after births as well as 7 to 28 days Zidovudine. N = 450.
      The study will be conducted at Ngamiani and Makorora Health Centres and Bombo Regional
      Hospital in Tanga, Tanzania as a cooperation between Rigshospitalet, Denmark, University of
      Copenhagen and National Institute of Medical Research, Tanzania.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of mother-to-child HIV transmission</measure>
    <time_frame>6 weeks post partum</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>frequency of NNRTI resistance development</measure>
    <time_frame>6 weeks post partum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of p24 antigen to HIV RNA for treatment induced changes in viremia</measure>
    <time_frame>Delivery, day 7, day 42 and month 9 post partum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of p24 antigen ability to detect viremia for the various subtypes A,C &amp; D</measure>
    <time_frame>Delivery, Day 7, Day 42 post partum, mother, Day 42 and Day 90 post partum child</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">566</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZT from week 28 or asap thereafter. Intrapartum AZT and 3TC + Single dose NVP Postpartum Combivir tail for 7 days twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZT from week 28 or asap thereafter. Intrapartum Single dose Truvada + Single dose NVP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine and Lamivudine (Combivir)</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine and Tenofovir (Truvada)</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected, antiretroviral naive, not fulfilling national Tanzanian criteria for
             HAART treatment, giving informed consent, consenting to homevisit-follow-up in case of
             no-show for scheduled hospital visit.

        Exclusion Criteria:

          -  CD4 less than 350 x10(6)/L, suffering from systemic diseases in need of medical
             treatment e.g. TB, renal or liver failure etc.

          -  Creatinin higher than 1,5 mg/dL, Alanine aminotransferase above 140 U/L
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terese L Katzenstein, MD Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bombo Regional Hospital</name>
      <address>
        <city>Tanga</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2006</study_first_submitted>
  <study_first_submitted_qc>June 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2006</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <name_title>Terese Katzenstein Consultant, MD, Ph.D. DMSc</name_title>
    <organization>Rigshospitalet</organization>
  </responsible_party>
  <keyword>mother-to-child-transmission</keyword>
  <keyword>PMTCT</keyword>
  <keyword>HIV</keyword>
  <keyword>resistance</keyword>
  <keyword>NNRTI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

